Sweden's Bonesupport Q3 revenue beats estimates on US segment growth

BoneSupport Holding AB

Today 07:14

Overview
Sweden orthobiologics firm's Q3 revenue rose 39% yr/yr, beating analyst expectations
Adjusted EPS for Q3 increased yr/yr
Company repurchased SEK 91.6 mln of shares under buyback program

Outlook
Company did not provide specific guidance for future quarters or the full year

Result Drivers
US SALES GROWTH - Co said strong sales growth in US segment drove overall revenue increase
EUROW SALES GROWTH - Co said sales growth in Europe & Rest of World segment contributed to revenue increase
REIMBURSEMENT CHANGE - CMS confirmed DRG reassignment for CERAMENT G, allowing higher reimbursement for qualifying cases

Company press release: ID:nMFNb58Kls

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
SEK 408.80 mln
SEK 389.33 mln (3 Analysts)
Q3 Adjusted EPS
 
SEK 1.41
 
Q3 Gross Margin
 
92.00%
 
Q3 EBIT
 
SEK 123.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Bonesupport Holding AB is SEK361.75, about 40.6% above its October 21 closing price of SEK257.20
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 35 three months ago

Reuters Recommended Reads
Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands
Oct 22 - Sweden's XVIVO Q3 revenue beat expectations on thoracic sales
Oct 22 - Sweden's Careium Q3 sales rise 21.6%, margin improves

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)